欧州実験生物学ジャーナル オープンアクセス

抽象的な

Comparison of antifungal effect of nanosilver particles alone and in combination with current drugs on candida species isolated from women with recurrent vulvovaginal candidiasis

Mehraban Falahati, Shima Nozari, Ayesheh Makhdoomi, Zeinab Ghasemi, Sanam Nami5 and Mehrdad Assadi

Vulvovaginal candidiasis may appear as an acute, chronic or recurrent genital infection that is caused due to overgrowth of Candida species, especially Candida albicans. Long-term, repetitive administration of common antifungal drugs causes resistance of candida species to these drugs. Therefore in order to achieve an optimum therapy we decided to examine the effects of common drugs in combination with nanosilver particles on the Candida species isolated from recurrent vaginal Candidiasis. This experimental study was performed on 30 Candida species isolated from women suffering from recurrent candidiasis. Direct a microscopic examination, culture and complementary tests such as culture on Candida Chrome Agar, formation of Germ tube, temperature test and sugar assimilation API 20c AUX were used to identify isolated Candida species. Minimum inhibitory concentration (MIC) of each common drug, nanosilver particles alone and their combination with nanosilver particles were performed with microdilution method according to NCCLS guideline and the results were analyzed with logistic regression, Chisquire and Mann – Whitney U test. In this study Candida albicans, C. glabrata, C. Krusei, C. tropicalis, C. parapsilosis and C. famata were isolated and identified, respectively, according to their abundance. The MICS of common drugs ranged from 4 to 128 μg/ml.The antifungal activities of these drugs in combination with nanosilver particles were more than when they were each used alone. Appropriate diagnosis of infectionin laboratory, using in vitro susceptibility tests and administration of topical formulations of nanosilver particles in combination with current drugs can be useful for treating vaginal candidiasis and preventing the disease recurrence.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません